| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 03/14/2013 | WO2013036562A1 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
| 03/14/2013 | WO2013036213A1 Dpp-iv inhibitor formulations |
| 03/14/2013 | WO2012175676A3 Molecules specifically binding pancreatic beta cells biomarkers |
| 03/14/2013 | WO2012122313A3 Targeted nanocarrier systems for delivery of actives across biological membranes |
| 03/14/2013 | US20130066069 Processes for preparing substituted pyrimidines |
| 03/14/2013 | US20130065883 Triazolo [4, 5- B] Pyridin Derivatives |
| 03/14/2013 | US20130065881 Tricyclic Compounds for Use as Kinase Inhibitors |
| 03/14/2013 | US20130065816 Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| 03/14/2013 | US20130064832 Notch inhibition in the treatment and prevention of a metabolic disease or disorder and cardiovascular complications thereof |
| 03/14/2013 | US20130064777 Surfactant-free water-free foamable compositions, breakable foams and gels their uses |
| 03/14/2013 | CA2846884A1 Pharmaceutical compositions comprising an aromatase inhibitor |
| 03/14/2013 | CA2845929A1 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
| 03/13/2013 | EP2567980A1 Use of neutralizing prolactin receptor antibodies for inhibition of lactation |
| 03/13/2013 | EP2567979A1 Use of neutralizing prolactin receptor antibodies for the treatment of hyper- and normoprolactinemic hair loss |
| 03/13/2013 | EP2567978A1 Use of neutralizing prolactin receptor antibodies for contraception |
| 03/13/2013 | EP2567977A1 Use of neutralizing prolactin receptor antibodies for the treatment of benign breast disease and mastalgia |
| 03/13/2013 | EP2566880A1 Aromatic-cationic peptides and uses of same |
| 03/13/2013 | EP2566877A1 Methods of reducing symptoms in subjects using single dosage forms with tapering release rates |
| 03/13/2013 | EP2566862A1 Benzofuranyl analogues as gpr119 modulators |
| 03/13/2013 | EP2566464A1 Pharmaceutical formulations comprising pioglitazone and linagliptin |
| 03/13/2013 | CN102961415A Application of phellinus lonicericola or extract thereof |
| 03/13/2013 | CN102961388A Medicine capable of promoting secretion of glp-1 and restraining secretion of gip |
| 03/13/2013 | CN102961359A Lumbrukinase enteric-coated pellet capsule and preparation method thereof |
| 03/13/2013 | CN102961358A Abiraterone acetate liquid capsule |
| 03/13/2013 | CN102961340A Nanoscale insulin and preparation method thereof |
| 03/13/2013 | CN102210873B Application of C10orf116 genes in preparing medicament for improving insulin sensitivity of adipose tissue |
| 03/13/2013 | CN102078394B Aconite extract-containing medicinal composition, preparation method and application thereof |
| 03/13/2013 | CN101745014B Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof |
| 03/13/2013 | CN101745010B Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof |
| 03/13/2013 | CN101745006B Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof |
| 03/13/2013 | CN101744987B Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof |
| 03/13/2013 | CN101056862B Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) |
| 03/12/2013 | US8394811 Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| 03/12/2013 | US8394369 Chondrocyte therapeutic delivery system |
| 03/12/2013 | CA2680946C Pim-3 kinase as a target for type 2 diabetes mellitus |
| 03/12/2013 | CA2480199C Fp-ghrelin |
| 03/12/2013 | CA2473927C Methods and compositions for treating polycystic ovary syndrome |
| 03/07/2013 | WO2013033283A1 Improving systemic glucose tolerance in type-2 diabetes |
| 03/07/2013 | WO2013032012A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | WO2013032011A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | US20130059867 Salt of fused heterocyclic derivative and crystal thereof |
| 03/07/2013 | US20130059828 Pharmaceutical composition |
| 03/07/2013 | CA2847336A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | CA2847334A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/06/2013 | EP2565185A1 [5,6]heterocyclic compound |
| 03/06/2013 | EP2563122A1 Chemical compounds |
| 03/06/2013 | CN102958908A New polymorphic form of calcimimetic compound |
| 03/06/2013 | CN102958907A New polymorphic form of calcimimetic compound |
| 03/06/2013 | CN102952059A Amide derivative and preparation method thereof, medicine composition and application |
| 03/06/2013 | CN102949721A Transdermal absorption pharmaceutical composition containing testosterone and NOS inhibitor |
| 03/06/2013 | CN102949542A Traditional Chinese medicine composite and preparation method thereof |
| 03/06/2013 | CN102949342A Transdermal absorption pharmaceutical composition containing testosterone |
| 03/06/2013 | CN102948758A Method for extracting buckwheat flavone from buckwheat bran |
| 03/06/2013 | CN102068447B Application of triterpenoid saponin compound in preparation of medicaments for treating autoimmune diseases |
| 03/06/2013 | CN101759743B Methylprednisolone aceponate monohydrate, crystal form and preparation method thereof |
| 03/05/2013 | US8389747 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly; preferred compound is picropodophyllin |
| 02/28/2013 | WO2012118412A3 Biologically active food additive for normalizing the function of the thyroid gland |
| 02/28/2013 | US20130053446 Pharmaceutical preparations having individualized dosage and structure |
| 02/28/2013 | US20130053431 Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| 02/28/2013 | US20130053412 Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| 02/28/2013 | US20130053371 Inhibitors of pi3 kinase |
| 02/28/2013 | US20130053367 Compounds and methods of treating diabetes |
| 02/28/2013 | US20130053346 Pyrimido-pyridazinone compounds and methods of use thereof |
| 02/28/2013 | US20130053338 Use of P2X Purinergic Receptor Agonists to Enhance Insulin Secretion in Pancreatic Beta Cells |
| 02/28/2013 | US20130052279 Reverse micelle system comprising metal ions and use thereof |
| 02/28/2013 | US20130052263 Pharmaceutical compositions with synchronized solubilizer release |
| 02/27/2013 | EP2560975A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists |
| 02/27/2013 | EP2560671A2 High affinity leptins and leptin antagonists |
| 02/27/2013 | CN102947338A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 02/27/2013 | CN102947275A Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| 02/27/2013 | CN102947274A Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| 02/27/2013 | CN102940880A Growth factor complex |
| 02/27/2013 | CN102940609A Octreotide sustained-release microspheres with high encapsulation rate and preparation method thereof |
| 02/27/2013 | CN101757631B Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration |
| 02/27/2013 | CN101289408B Non-steroid progestogen receptor regulator, preparation thereof, pharmaceutical compositions and uses |
| 02/26/2013 | CA2632013C Adenovirus 36 e4 orf 1 gene and protein and their uses |
| 02/26/2013 | CA2389644C A novel polypeptide hormone phosphatonin |
| 02/21/2013 | WO2013023617A1 Novel bioactive protein isolated fron chinese yam and uses thereof |
| 02/21/2013 | WO2013023300A1 Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
| 02/21/2013 | WO2013006451A3 Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof |
| 02/21/2013 | US20130046013 Salicylate fatty acid derivatives |
| 02/21/2013 | US20130045994 Pyridine derivative |
| 02/21/2013 | US20130045271 Steroid hormone delivery systems and methods of preparing the same |
| 02/21/2013 | US20130045213 Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity |
| 02/21/2013 | US20130045194 Delivery of Cholesteryl Ester to Steroidogenic Tissues |
| 02/21/2013 | US20130045186 Method of Detecting and/or Identifying Adeno-Associated Virus (AAV) Sequences and Isolating Novel Sequences Identified Thereby |
| 02/20/2013 | EP2559705A2 Anti-activin a antibodies and uses thereof |
| 02/20/2013 | EP2558076A2 Low-dosed solid oral dosage forms for hrt |
| 02/20/2013 | CN102935231A Treatments using citrulline |
| 02/20/2013 | CN102086197B Protoberberine derivative with insulin-sensitizing activity and application thereof |
| 02/19/2013 | US8378118 Pyrazole-based thyroid receptor compounds |
| 02/19/2013 | US8377950 Crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt |
| 02/19/2013 | US8377880 Therapeutic agents for reducing parathyroid hormone levels |
| 02/19/2013 | CA2486187C Kinase inhibitors |
| 02/14/2013 | WO2013022091A1 Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| 02/14/2013 | WO2013020996A1 Composition for controlled ovarian stimulation |
| 02/14/2013 | WO2013020372A1 Methods and reagents for preventing and curing insulin resistance and diabetes mellitus |
| 02/14/2013 | WO2013020215A1 Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| 02/14/2013 | US20130041007 Selective Androgen Receptor Modulators |
| 02/14/2013 | US20130041000 Novel azole compound |